Clinical Development Plan: What It Should Include

Early clinical planning is often treated as a timeline exercise. It is more useful as a decision exercise. A strong clinical development plan makes the program’s most important questions visible: what must be true for the product to matter, what evidence will answer that question, and what needs to happen before a team can responsibly spend more time and capital.

For startup and university teams, this matters because clinical, regulatory, quality, product, business, team, and fundraising decisions rarely arrive one at a time. A change in intended use, patient population, endpoint, or evidence standard can reshape study feasibility, supply needs, risk, budget, and the story a team needs to tell investors. The plan is the shared reference that keeps those decisions connected.

Start with the decision, not the study

The first question is not “What trial should we run?” It is “What decision will this evidence support?” That decision might concern safety, technical feasibility, dose, target population, clinical performance, or whether to advance the program at all. A study can be well executed and still leave a team uncertain if its central question was never defined.

The ICH’s general considerations for clinical studies emphasize clear objectives, fit-for-purpose information, and proactive quality planning. Put plainly: identify the question, define what an informative answer looks like, and design the work around the factors that could prevent that answer from being reliable.

What a clinical development plan should include

The format will differ by product and stage, but the sections below give a practical starting point. The value is not in producing a long document. It is in making the logic between sections explicit.

1. Product, intended use, and patient context

Describe the product in terms that matter for the clinical question: the intended use, target user or patient population, setting of use, and the unmet need being addressed. For a device, include the decision-driving features and how they are expected to influence clinical performance. For a therapeutic program, clarify the disease setting, treatment context, and the clinical benefit the program intends to demonstrate.

2. Evidence already in hand and the gaps that remain

Separate what is known from what is assumed. Capture relevant nonclinical work, prior human data, published evidence, usability or performance findings, and the limitations of each. Then state the evidence gaps in plain language. This prevents a plan from becoming a list of activities without a reason for each activity.

3. The sequence of studies and decision points

For each proposed study, describe its objective, the question it answers, the population, the key endpoint or outcome, the decision it supports, and what result would change the next step. The sequence should show dependencies. A pivotal-style study cannot carry an unresolved question that belongs in an earlier feasibility or exploratory study.

4. Regulatory and quality considerations

Bring regulatory affairs and quality assurance into the plan while options are still open. The FDA’s clinical-trial guidance library shows how guidance spans study design, human-subject protection, safety reporting, data, and specific product contexts. The applicable path needs to be assessed for the actual product and jurisdiction, not borrowed from a superficially similar program.

Quality planning should focus attention on what is critical to participant protection and to reliable, decision-useful data. That includes protocol feasibility, data collection, site capability, monitoring, product accountability, and the safeguards required for the study’s risk profile. It does not mean adding process for its own sake.

5. Feasibility, operations, and resources

A plan needs an honest view of how the work will be done. Consider likely sites, investigator and staff needs, recruitment realities, study product availability, vendor roles, data-management needs, timing, and budget ranges. These are not afterthoughts. If a proposed population is difficult to reach or a critical assay is not ready, the evidence sequence may need to change.

6. Risks, assumptions, and update triggers

List the assumptions that could move the plan, such as a regulatory interaction, an early readout, a change in standard of care, or a manufacturing constraint. Pair meaningful risks with owners and mitigation options. Then specify when the plan will be reviewed. Good triggers include new safety data, the completion of a study, a regulatory meeting, material protocol feedback, or a change in the product’s intended use.

Keep strategy and execution connected

A clinical development plan works best when it stays connected to the rest of the venture. The product’s intended use informs the clinical evidence needed. The evidence path affects regulatory timing and quality priorities. Those choices influence the budget, the capabilities the team needs, and the milestones that make a fundraising conversation credible.

This is why a plan should be written with the people who will have to act on it. Clinical, regulatory, quality, product, operations, and business perspectives can uncover different risks in the same proposed study. The plan does not eliminate disagreement. It gives the team a disciplined place to resolve it before the disagreement becomes a costly delay.

A practical first-pass checklist

1. Write the single most important decision the next body of evidence must support.
2. Define the patient, use context, and product claim or clinical benefit relevant to that decision.
3. List the evidence already available, including its limits.
4. Identify the study or analysis most likely to close the highest-priority gap.
5. State the endpoint, feasibility assumptions, and decision criteria before committing to detailed execution.
6. Map the regulatory, quality, operational, and supply dependencies that could affect the sequence.
7. Set the next review point and record what new information would cause the plan to change.

How Nexus Life Sciences can help

Nexus Life Sciences helps teams connect clinical programs, regulatory affairs, and quality assurance with the product, business plan, team, and fundraising decisions around them. The goal is not a generic template. It is a clearer development path that reflects the work, questions, and stage of the venture in front of you.

For startup teams and university innovators, an early working plan can create a more focused next conversation, whether that is a product decision, a clinical evidence question, a regulatory discussion, or preparation for a financing milestone. Book a consultation to discuss the work ahead.